BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 15254192)

  • 1. Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.
    Stevens R; Howard KE; Nordone S; Burkhard M; Dean GA
    J Virol; 2004 Aug; 78(15):8210-8. PubMed ID: 15254192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
    Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
    Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
    Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
    AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
    Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
    Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
    Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
    AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus.
    Tijhaar EJ; Huisman W; Huisman RC; Siebelink KH; Karlas JA; de Ronde A; van Herwijnen R; Mooi FR; Osterhaus AD
    J Gen Virol; 1997 Dec; 78 ( Pt 12)():3265-75. PubMed ID: 9400977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.
    Lockridge KM; Chien M; Dean GA; Stefano Cole K; Montelaro RC; Luciw PA; Sparger EE
    Virology; 2000 Jul; 273(1):67-79. PubMed ID: 10891409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag.
    Zhao X; Zhang M; Li Z; Frankel FR
    J Virol; 2006 Sep; 80(18):8880-90. PubMed ID: 16940500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus.
    Finerty S; Stokes CR; Gruffydd-Jones TJ; Hillman TJ; Barr FJ; Harbour DA
    Vaccine; 2001 Oct; 20(1-2):49-58. PubMed ID: 11567745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication.
    Boyer JD; Robinson TM; Maciag PC; Peng X; Johnson RS; Pavlakis G; Lewis MG; Shen A; Siliciano R; Brown CR; Weiner DB; Paterson Y
    Virology; 2005 Mar; 333(1):88-101. PubMed ID: 15708595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection.
    Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D
    Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
    Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H
    Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feline immunodeficiency virus Gag- and Env-specific immune responses after vaginal versus intravenous infection.
    Burkhard MJ; Mathiason CK; Bowdre T; Hoover EA
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1767-78. PubMed ID: 11788028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS.
    Klonjkowski B; Klein D; Galea S; Gavard F; Monteil M; Duarte L; Fournier A; Sayon S; Górna K; Ertl R; Cordonnier N; Sonigo P; Eloit M; Richardson J
    Vaccine; 2009 Feb; 27(6):928-39. PubMed ID: 19070641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
    Leutenegger CM; Boretti FS; Mislin CN; Flynn JN; Schroff M; Habel A; Junghans C; Koenig-Merediz SA; Sigrist B; Aubert A; Pedersen NC; Wittig B; Lutz H
    J Virol; 2000 Nov; 74(22):10447-57. PubMed ID: 11044089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
    Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE
    J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats.
    Burkhard MJ; Valenski L; Leavell S; Dean GA; Tompkins WA
    Vaccine; 2002 Dec; 21(3-4):258-68. PubMed ID: 12450701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccination using expression vectors carrying FIV structural genes induces immune response against feline immunodeficiency virus.
    Cuisinier AM; Mallet V; Meyer A; Caldora C; Aubert A
    Vaccine; 1997 Jul; 15(10):1085-94. PubMed ID: 9269051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination.
    Flynn JN; Keating P; Hosie MJ; Mackett M; Stephens EB; Beatty JA; Neil JC; Jarrett O
    J Immunol; 1996 Oct; 157(8):3658-65. PubMed ID: 8871667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.